Taich Adam 4

What Happened

• Adam Taich, Chief Financial Officer of 10x Genomics (TXG), was granted 106,579 restricted stock units (RSUs) on February 26, 2026. The grant is reported as an acquisition at $0.00 (no cash paid at grant). This is a compensation award, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-26; Form 4 filed: 2026-03-02 (filed within the standard two-business-day window).
• Transaction type/code: A — Grant/Award (RSUs).
• Shares granted: 106,579 RSUs; reported price: $0.00; total reported cash value at acquisition: $0.
• Vesting: Each RSU converts to one share upon vesting. 1/12th of the RSUs vest on each quarterly anniversary beginning February 21, 2026 (i.e., quarterly over 12 quarters, subject to continued service).
• Shares owned after transaction: Not specified in the provided Form 4 excerpt.

Context

• These RSUs are a common form of executive compensation and are contingent on continued service; they do not represent an immediate sale or purchase of shares. The award will translate into actual shares only as the RSUs vest over time.